Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

More than 500,000 Britons are believed to be using weight loss drugs but a waning appetite is not all they report – there’s also a lack of desire to drink alcohol ...

The ad came in response to Hims & Hers' controversial ... $11.5 billion of this was driven by Mounjaro, with sales of the GLP-1 drug growing 124% year-on-year.

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Social media is alight with people who are sharing their experience of constant internal chatter about food. This so-called ...

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs ...

Advertisement Article continues below this ad The injectable drugs have been in shortage since 2022. In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another ...

Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...